FDA Seeks Risk-Based Inspection Program

FDA's new policies intend to make GMP inspections more efficient and apply to stricter rules to high-risk products and processes.

Related Content:

Regulatory WatchPharmaceutical Technology-11-02-2003

Biosimilars Move to Center Stage

CMA Fines Advanz for Over-Pricing Liothyronine Tablets

FDA Prioritizes Vaccine Review and Process Improvements